Hemodynamic effects of adrenergic stimulating and blocking agents in cardiogenic shock and low output state after myocardial infarction.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D004357:Drug Synergism; D005260:Female; D006321:Heart / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007545:Isoproterenol / Q000008:administration & dosage / Q000627:therapeutic use*; D007773:Lactates / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000008:administration & dosage / Q000627:therapeutic use*; D010101:Oxygen Consumption; D010643:Phenoxybenzamine / Q000008:administration & dosage / Q000627:therapeutic use*; D012770:Shock, Cardiogenic / Q000188:drug therapy*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D007773:Lactates; D010643:Phenoxybenzamine; D007545:Isoproterenol; D009638:Norepinephrine